Jon Napitupulu

Tiziana Life Sciences’ intranasal foralumab has cleared an important credibility hurdle with the peer-reviewed publication of its open-label study...

Ascendis Pharma will report full-year 2025 results and host a business update on February 11, 2026, after the U.S....

HighLife has secured CE Mark approval for its transfemoral Transcatheter Mitral Valve Replacement system, enabling initial commercial availability across...

NMD Pharma reported topline Phase 2a results for ignaseclant in Charcot‑Marie‑Tooth disease (CMT) showing the study did not meet...

Ascendis Pharma will report full-year 2025 financials and deliver a business update on February 11, 2026, after U.S. market...

Adaptive Biotechnologies reported a breakout 2025: total revenue rose 55% to $277 million, driven by 46% growth in its...

Ocular Therapeutix has granted inducement equity awards to five newly hired non-executive employees, including options to purchase 13,850 shares...

XORTX Therapeutics has extended the deadline to close its acquisition of Vectus Biosystems’ renal anti‑fibrotic program, including the novel...

Syndax Pharmaceuticals will spotlight its strategy at the 2026 Guggenheim Emerging Outlook: Biotech Summit on February 12, with a...

Rhythm Pharmaceuticals will put its finance chief on stage next week. The company’s CFO is scheduled for a fireside...